Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

The market currently rewards development-stage biotechs with high-potential pipeline catalysts more than profitable companies facing drug launch complexities. Investors are drawn to the upside of a "golden ticket" clinical result, finding it more attractive than modeling quarterly sales, inventory, and other commercial realities.

Cogent's CEO argues that biotech investors often overlook proven modalities like targeted therapies in favor of "sexy" categories like AI or gene therapy. He believes that even if a drug doesn't fit a hyped trend, impressive clinical outcomes will ultimately win, making these less-hyped areas underappreciated.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

Early in his career, Andy Robbins dismissed the potential of Revlimid, a drug that became a blockbuster. This mistake taught him to focus first on finding great science that solves a problem and then building a commercial strategy, rather than trying to fit science into a predefined large market.

Contrary to the industry's meritocratic ideal, superior science and clinical data do not guarantee success. Cogent's CEO asserts that he watched for years as companies with inferior results but more effective PR and investor relations campaigns were rewarded by the market.

The current biotech bull market is fundamentally different from past rallies. It's driven by small and mid-sized companies successfully launching products and generating revenue, shifting the sector from a "dream-based" industry to one focused on execution and profitability.

The industry over-celebrates financial winners. Equal praise should be given to leaders who, despite poor financial outcomes, successfully pioneer new scientific ground or persevere to get a drug approved for a high unmet need. Their work provides crucial groundwork for future successes.